EDIT vs SLB · rev $32.3M vs P/E 12, rev $35.71B
Editas Medicine Inc (EDIT) versus Schlumberger NV (SLB) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Schlumberger NV (SLB) is a oil & gas equipment & services company listed on US.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported SLB revenue for 2025-12-31 was $35.71B. Net income was $3.37B. Revenue was down 1.6% from 2024-12-31 to 2025-12-31. SLB currently screens at market cap $48.16B and trailing P/E 12.1.
EDIT currently screens at market cap $375.2M. SLB currently screens at market cap $48.16B and trailing P/E 12.1.
Not investment advice. Open the EDIT and SLB stock pages for the full models.
Not investment advice.